Talquetamab-tgvs

{
  "id": "MLC-T-ONC-016973",
  "term": "Talquetamab-tgvs",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab-tgvs binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.",
  "synonyms": [
    "talquetamab",
    "humanized GPRC5D x CD3 DuoBody antibody JNJ-64407564",
    "GPRC5D x CD3 DuoBody antibody JNJ-64407564",
    "GPRC5D/CD3 DuoBody antibody JNJ-64407564",
    "anti-CD3/anti-GPRC5D bispecific monoclonal antibody JNJ-64407564",
    "GPRC5D x CD3 bispecific antibody JNJ-64407564"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/talquetamab-tgvs/"
}